Congress passed a five‑year reauthorization of the SBIR and STTR programs, restoring seed‑funding pathways for small U.S. biotech companies that underpin early translational work. The Biotechnology Innovation Organization (BIO) flagged the move as critical for sustaining innovation and U.S. leadership in life sciences; the programs have historically supported a meaningful fraction of FDA‑approved drugs. BIO and federal agencies will now prepare to reopen applications—an immediate operational signal for small firms that rely on non‑dilutive grants to reach value‑creating milestones and attract venture backing.